Effect of Hesperetin on the Antidepressant Activity of Electroconvulsive Therapy in an Enforced Reserpine Model of Depression in Male Rats

IF 0.5 Q4 PSYCHIATRY

Iranian Journal of Psychiatry and Behavioral Sciences Pub Date : 2022-12-26 DOI:10.5812/ijpbs-122915

Acieh Alizadeh Makvandi, M. Khalili, M. Roghani

{"title":"Effect of Hesperetin on the Antidepressant Activity of Electroconvulsive Therapy in an Enforced Reserpine Model of Depression in Male Rats","authors":"Acieh Alizadeh Makvandi, M. Khalili, M. Roghani","doi":"10.5812/ijpbs-122915","DOIUrl":null,"url":null,"abstract":"Background: Depression is a common and debilitating disorder of the brain. Many pharmacological therapies, including many plant components (such as flavonoids), are used to treat depression. Electroconvulsive therapy (ECT) is a useful method for depressed patients who do not respond to medication. However, this method has some side effects. Hence, investigators have tried to improve ECT’s positive points by diminishing its side effects. Objectives: We investigated the effect of hesperetin (a flavonoid component) on the antidepressant activity of ECT in an enforced reserpine model of depression in male rats. Methods: Eighty male rats (230 - 250 g) were randomly divided into control, ECT + reserpine (Res), Res + hesperetin (Hes; 10 or 20 mg/kg), Res + ECT, and Res + ECT + Hes (10 or 20 mg/kg) groups. The effects of hesperetin were evaluated by the forced swimming test (FST), sucrose preference test (SPT), open field test (OFT), elevated plus maze test (EPMT), as well as by measurement of the brain-derived neurotrophic factor (BDNF) and oxidative stress biomarkers [ie, malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione (GSH)] in the prefrontal cortex area. Results: The outcomes of the behavioral experiments showed that Hes + ECT treatment could raise the percentage of open arm entrance in EPMT, anhedonia in SPT, and decrease immobilization time in FST compared to the groups treated with ECT (P < 0.05) or hesperetin alone. Our biochemical research also illustrated a significant reduction in MDA in the groups treated with ECT + Hes (10 or 20 mg/kg; P < 0.01 and P < 0.001) and ECT or hesperetin, as well as a significant increase in GSH, SOD, and BDNF in the ECT + Hes (20 mg/kg) animal group (P < 0.001). Conclusions: In depressed rats, the ECT linked to the application of hesperetin could significantly elevate BDNF, GSH, and SOD reduction in depressed male rats.","PeriodicalId":46644,"journal":{"name":"Iranian Journal of Psychiatry and Behavioral Sciences","volume":" ","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Psychiatry and Behavioral Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/ijpbs-122915","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Depression is a common and debilitating disorder of the brain. Many pharmacological therapies, including many plant components (such as flavonoids), are used to treat depression. Electroconvulsive therapy (ECT) is a useful method for depressed patients who do not respond to medication. However, this method has some side effects. Hence, investigators have tried to improve ECT’s positive points by diminishing its side effects. Objectives: We investigated the effect of hesperetin (a flavonoid component) on the antidepressant activity of ECT in an enforced reserpine model of depression in male rats. Methods: Eighty male rats (230 - 250 g) were randomly divided into control, ECT + reserpine (Res), Res + hesperetin (Hes; 10 or 20 mg/kg), Res + ECT, and Res + ECT + Hes (10 or 20 mg/kg) groups. The effects of hesperetin were evaluated by the forced swimming test (FST), sucrose preference test (SPT), open field test (OFT), elevated plus maze test (EPMT), as well as by measurement of the brain-derived neurotrophic factor (BDNF) and oxidative stress biomarkers [ie, malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione (GSH)] in the prefrontal cortex area. Results: The outcomes of the behavioral experiments showed that Hes + ECT treatment could raise the percentage of open arm entrance in EPMT, anhedonia in SPT, and decrease immobilization time in FST compared to the groups treated with ECT (P < 0.05) or hesperetin alone. Our biochemical research also illustrated a significant reduction in MDA in the groups treated with ECT + Hes (10 or 20 mg/kg; P < 0.01 and P < 0.001) and ECT or hesperetin, as well as a significant increase in GSH, SOD, and BDNF in the ECT + Hes (20 mg/kg) animal group (P < 0.001). Conclusions: In depressed rats, the ECT linked to the application of hesperetin could significantly elevate BDNF, GSH, and SOD reduction in depressed male rats.

查看原文本刊更多论文

Hesperetin对雄性大鼠强迫利血平抑郁模型电惊厥治疗抗抑郁活性的影响

背景：抑郁症是一种常见的使人衰弱的大脑疾病。许多药物疗法，包括许多植物成分（如黄酮类化合物），都被用于治疗抑郁症。电休克治疗（ECT）是治疗对药物没有反应的抑郁症患者的一种有用方法。然而，这种方法也有一些副作用。因此，研究人员试图通过减少ECT的副作用来提高ECT的积极性。目的：在雄性大鼠强制利血平抑郁模型中，研究橙皮素（一种黄酮类成分）对ECT抗抑郁活性的影响。方法：80只雄性大鼠（230～250g）随机分为对照组、ECT+利血平（Res）组、Res+橙皮素（Hes；10或20mg/kg）组、Res+ECT组和Res+ECT+Hes（10或20mgg/kg）组。通过强迫游泳试验（FST）、蔗糖偏好试验（SPT）、开放场地试验（OFT）、提升加迷宫试验（EPMT）以及测量前额叶皮层区域的脑源性神经营养因子（BDNF）和氧化应激生物标志物[即丙二醛（MDA）、超氧化物歧化酶（SOD）和谷胱甘肽（GSH）]来评估橙皮素的作用。结果：行为实验结果表明，与单独用ECT或橙皮素治疗的组相比，Hes+ECT治疗可提高EPMT的张开臂进入百分比、SPT的快感缺乏，并缩短FST的固定时间（P<0.05）。我们的生化研究还表明，ECT+Hes（10或20 mg/kg；P<0.01和P<0.001）和ECT或橙皮素治疗组的MDA显著降低，ECT+Hes（20 mg/kg）动物组的GSH、SOD和BDNF显著增加（P<0.001），GSH和SOD的降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Iranian Journal of Psychiatry and Behavioral Sciences PSYCHIATRY-

CiteScore

1.20

自引率

10.00%

发文量

期刊介绍： The Iranian Journal of Psychiatry and Behavioral Sciences (IJPBS) is an international quarterly peer-reviewed journal which is aimed at promoting communication among researchers worldwide and welcomes contributions from authors in all areas of psychiatry, psychology, and behavioral sciences. The journal publishes original contributions that have not previously been submitted for publication elsewhere. Manuscripts are received with the understanding that they are submitted solely to the IJPBS. Upon submission, they become the property of the Publisher and that the data in the manuscript have been reviewed by all authors, who agree to the analysis of the data and the conclusions reached in the manuscript. The Publisher reserves copyright and renewal on all published material and such material may not be reproduced without the written permission of the Publisher. Statements in articles are the responsibility of the authors.